Cue Biopharma, Inc.
CUE
$0.7767
$0.00831.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -52.76% | 25.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -52.76% | 25.51% | |||
| Cost of Revenue | 15.36% | -11.01% | |||
| Gross Profit | -59.53% | 25.13% | |||
| SG&A Expenses | -62.28% | 7.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.52% | -6.08% | |||
| Operating Income | -8.05% | 14.17% | |||
| Income Before Tax | -9.65% | 14.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.65% | 14.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.65% | 14.86% | |||
| EBIT | -8.05% | 14.17% | |||
| EBITDA | -8.17% | 14.32% | |||
| EPS Basic | 24.32% | 16.63% | |||
| Normalized Basic EPS | 25.19% | 15.71% | |||
| EPS Diluted | 24.32% | 16.63% | |||
| Normalized Diluted EPS | 25.19% | 15.71% | |||
| Average Basic Shares Outstanding | 44.91% | 2.10% | |||
| Average Diluted Shares Outstanding | 44.91% | 2.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||